The CCR2/CCR5 antagonist BMS-81316 is currently being tested in the neoadjuvant setting in combination with nivolumab and/or GVAX in locally advanced pancreatic ductal adenocarcinomas (NCT03767582), or with anti-IL-8 in non-small cell lung cancer (NSCLC) or hepatocellular carcinoma (HCC) (NCT04123379). Here, CCR5 is linked to hepatocellular carcinoma.